The PISCES study, published in the NEJM, demonstrated that daily intake of fish oil lessens the hazard of major cardiovascular occurrences in dialysis patients. The trial involved 1,228 individuals from Australia and Canada. This is pertinent only for those on hemodialysis.
Daily consumption of fish oil nearly halves the chance of serious cardiovascular complications among people undergoing dialysis treatment. Scientists arrived at this conclusion through the largest international clinical trial, named PISCES, with results released in the esteemed New England Journal of Medicine (NEJM).
This investigation factored in data from 1,228 participants across 26 medical centers located in Australia and Canada. Patients who consumed four grams of fish oil daily, rich in active EPA and DHA acids, were 43 percent less likely to encounter heart attacks, strokes, cardiac fatalities, and vessel amputations compared to those receiving a placebo. Experts stress that in dialysis patients, EPA and DHA levels are often substantially below normal parameters, which may account for the pronounced protective impact of fish oil.
Additionally, researchers clarify that these findings are relevant exclusively for individuals with renal failure who are undergoing hemodialysis. These conclusions should not be extended to healthy people or other patient groups.
In October, investigators determined that combining fermented kefir and dietary fiber reduces inflammatory processes considerably more effectively than omega-3.
About the Author
